NCT05967156 is a NA clinical trial of Empagliflozin10Mg Tab in Heart Failure, sponsored by Shahid Beheshti University of Medical Sciences.

Who is sponsoring NCT05967156?

NCT05967156 is sponsored by Shahid Beheshti University of Medical Sciences.

What drugs are being tested in NCT05967156?

Interventions in NCT05967156: Empagliflozin10Mg Tab.

What condition does NCT05967156 study?

NCT05967156 studies Heart Failure, Hemodialysis.

Is NCT05967156 still recruiting?

NCT05967156 is currently completed. Last updated 6 June 2025.

Last reviewed 2025-06-06 · How we verify

NCT05967156

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Empagliflozin in Heart Failure Dialysis Patients

Completed NA Last updated 6 June 2025

What this trial tests

NA trial testing Empagliflozin10Mg Tab in Heart Failure in 30 participants. Completed in 3 June 2025.

Timeline

1 June 2023

Primary endpoint
1 June 2025

3 June 2025

Quick facts

Lead sponsor	Shahid Beheshti University of Medical Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 June 2023
Primary completion	1 June 2025
Estimated completion	3 June 2025
Sites	1 location across Iran

Drugs / interventions tested

Empagliflozin10Mg Tab — full drug profile →

Conditions studied

Heart Failure — all drugs for Heart Failure →
Hemodialysis — all drugs for Hemodialysis →

Sponsor

Shahid Beheshti University of Medical Sciences

Who can join

Eligibility, any sex, with Heart Failure or Hemodialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Empagliflozin is not still approved for glomerular filtration rate \< 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
Siddiqui R, Obi Y, Dossabhoy NR, Shafi T. · · 2024 · cited 15× · PMID 38913113 · DOI 10.1007/s11906-024-01314-3
SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art.
Minutolo R, Ruotolo C, Conte G, Borrelli S. · · 2026 · cited 2× · PMID 41487902 · DOI 10.1093/ckj/sfaf350
The Intertwined Challenge: A Prospective Assessment of Empagliflozin Safety in Hemodialysis-Dependent Patients with Heart Failure
Ahmadi N, Nikmanesh M, Anvari S, heidari S, et al · · 2025 · DOI 10.21203/rs.3.rs-7667019/v1

Verify or expand the search:

Other trials of Empagliflozin10Mg Tab

Trials testing the same drug.

NCT07379788 — ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling · recruiting
NCT04906213 — CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients · Phase 2 · terminated

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Shahid Beheshti University of Medical Sciences trials

Trials by the same sponsor.

NCT07005687 — Using MSCs for Chronic Active Antibody Mediated Rejection · NA · not yet recruiting
NCT07435558 — Homogeneous vs. Heterogeneous Learning Style Grouping in Problem-Based Learning Among Nurses · NA · not yet recruiting
NCT07408492 — Impact of AI-Based Research Training on Nursing Students · NA · not yet recruiting
NCT07176663 — Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure · NA · not yet recruiting
NCT07291622 — Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05967156 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shahid Beheshti University of Medical Sciences
Last refreshed: 6 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05967156.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing